LEQEMBI Gets Patent Boost: FDA Extends Drug Monopoly Time
Published Date: 12/29/2025
Notice
Summary
The FDA has officially set the review period for LEQEMBI, a new medicine, so its patent can be extended. This helps the company protect their invention longer, which might affect when generic versions can appear. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they must act by early 2026.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA Sets LEQEMBI Review Period
The FDA determined LEQEMBI's regulatory review period is 4,546 days (4,300 days testing phase and 246 days approval phase) using these dates: IND effective July 29, 2010; BLA submitted May 6, 2022; approval January 6, 2023. This determination establishes the maximum potential length of any patent term extension, and the applicant has requested a 5-year patent extension.
Deadlines To Challenge Dates or Diligence
Anyone who believes the published dates are incorrect must request a redetermination by February 27, 2026. Any interested person may petition FDA to challenge whether the applicant acted with due diligence during the regulatory review period by June 29, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in